10-Q: Mineralys Therapeutics Advances Hypertension Drug Towards NDA

Mineralys Therapeutics reports strong clinical trial results for lorundrostat in hypertension and chronic kidney disease, bolstering its path to an NDA submission in late 2025 or early 2026.

Summary

• Reported positive results from pivotal Phase 3 Launch-HTN and Phase 2 Advance-HTN trials for lorundrostat in uncontrolled or resistant hypertension.
• Announced positive topline data from Phase 2 Explore-CKD trial for lorundrostat in hypertensive participants with Stage 2 to 3b chronic kidney disease.
• Initiated and completed enrollment for Phase 2 Explore-OSA trial for obstructive sleep apnea and hypertension, with topline results expected in the first quarter of 2026.
• Plans to submit a New Drug Application (NDA) for lorundrostat in late 2025 or the first quarter of 2026.
• Ended Q3 2025 with $593.6 million in cash, cash equivalents, and investments, which is believed to be sufficient to fund operations for at least 12 months.
• Net loss for the nine months ended September 30, 2025, was $122.4 million, an improvement from $128.9 million in the prior year period.
• Successfully raised significant capital through public offerings in March and September 2025, totaling $458.3 million net, and $27.3 million through an At-The-Market (ATM) facility, which has since been terminated.

Sentiment

Score: 8

Explanation: The company reported strong positive clinical trial results for its lead candidate, lorundrostat, across multiple indications, including pivotal hypertension trials and a Phase 2 CKD trial. This significantly de-risks the development pathway and supports the planned NDA submission. The company also successfully raised substantial capital, bolstering its liquidity and extending its cash runway. While still pre-revenue and incurring losses, the clinical progress and financial strength are very positive indicators for a clinical-stage biopharmaceutical company.

Positives

• Lorundrostat's pivotal Phase 3 Launch-HTN trial achieved statistically significant and clinically meaningful mean reductions in placebo-adjusted systolic BP of -9.1 mmHg at week six (p<0.0001) and -11.6 mmHg at week 12 (p<0.0001).
• The Phase 2 Advance-HTN trial also met its primary endpoint with a statistically significant and clinically meaningful mean reduction in placebo-adjusted 24-hour ambulatory systolic BP of -7.9 mmHg at week 12 (p=0.001).
• The Explore-CKD Phase 2 trial showed highly statistically significant and clinically meaningful results, including a placebo-adjusted systolic BP reduction of -7.5 mmHg (p=0.0024) and a urine albumin-to-creatinine ratio (UACR) reduction of -25.60% (p=0.0015).
• Clinical safety findings across pivotal trials, including adrenocorticotropic hormone-stimulated and serum cortisol, change in serum potassium, serum sodium, and estimated glomerular filtration rate (eGFR), as well as incidence of hypotension, support a favorable benefit-risk profile for lorundrostat.
• Strong cash position with $593.6 million in cash, cash equivalents, and investments as of September 30, 2025, providing a runway for at least 12 months.
• Successfully completed two public offerings in March and September 2025, raising $188.7 million and $269.6 million net, respectively, significantly bolstering liquidity.
• Net loss for the nine months ended September 30, 2025, decreased to $122.4 million from $128.9 million in the prior year period, indicating a reduced rate of loss.
• Research and development expenses decreased by $16.4 million for the nine months ended September 30, 2025, primarily due to the conclusion of the lorundrostat pivotal program.

Negatives

• Continued to incur significant operating losses, with an accumulated deficit of $424.9 million as of September 30, 2025.
• Net cash used in operating activities increased to $104.5 million for the nine months ended September 30, 2025, from $99.5 million in the prior year period, indicating increased cash burn from operations.
• General and administrative expenses increased by $8.1 million for the nine months ended September 30, 2025, reflecting increased costs associated with operating as a public company and supporting R&D activities.
• Incidence of confirmed hyperkalemia (serum potassium >6.0 mmol/L) was observed in clinical trials (0.6% to 3.2% in pivotal trials after excluding spurious results, and 5% in Explore-CKD), which is a known side effect of aldosterone pathway inhibitors.
• A modest decrease in mean eGFR (-4.6% placebo-adjusted) was observed in the Explore-CKD trial, which is an anticipated effect of renin-angiotensin-aldosterone pathway inhibitors.

Risks

• Changes in trade policy and inflation could adversely affect business and results of operations by increasing costs for commodities, labor, materials, and services, and making additional financing more difficult or costly.
• New tax laws, such as the Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act (OBBBA), or changes in their implementation or interpretation, may materially adversely affect financial condition, results of operations, and cash flows.
• Disruptions at the FDA and other government agencies, including potential government shutdowns (e.g., the ongoing shutdown that began October 1, 2025), could hinder their ability to timely review and process regulatory submissions, including the planned NDA for lorundrostat.
• Inability to raise additional funds or enter into strategic arrangements when needed on favorable terms or at all could force delays, limits, reductions, or termination of product development or future commercialization efforts.
• The process of testing product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is inherently uncertain.

Future Outlook

The company plans to submit a New Drug Application (NDA) for lorundrostat in late 2025 or the first quarter of 2026, based on positive results from its pivotal Launch-HTN and Advance-HTN trials. It also anticipates reporting topline results from the Phase 2 Explore-OSA trial in the first quarter of 2026. The company expects to continue incurring substantial losses as it advances clinical development, seeks regulatory approvals, and expands commercialization capabilities, and plans to finance future operations through equity offerings, debt financings, or strategic collaborations.

Management Comments

• "Our research and development has been committed to clinical trials researching the benefits of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) and hypertensive patients with CKD and OSA."
• "Based on the positive results from our pivotal program, we plan to submit an NDA in late 2025 or during the first quarter of 2026."
• "We also believe, based on available clinical data, that our product candidate holds promise to be an innovative solution for the rapidly growing unmet need in multiple cardiorenal metabolic disorders."
• "We believe clinical safety findings in the two pivotal trials, including adrenocorticotropic hormone-stimulated and serum cortisol, change in serum potassium, serum sodium, and estimated glomerular filtration rate (eGFR), as well as incidence of hypotension, support a favorable benefit-risk profile."
• "The reduction in UACR observed in this trial is consistent with the potential of lorundrostat to have renal protective effects."
• "Based on our current operating plan, we believe that our cash, cash equivalents, and investments as of September 30, 2025 will be sufficient to allow us to fund our operations for at least twelve months."

Industry Context

Mineralys Therapeutics is developing lorundrostat, an aldosterone synthase inhibitor (ASI), to address dysregulated aldosterone, a key factor in approximately 30% of hypertensive patients. With over 30 million treated patients in the U.S. failing to achieve their blood pressure goals, and a significant portion having systolic BP greater than 140 mmHg, there is a substantial unmet medical need. Lorundrostat's positive pivotal trial results position it as a potential innovative solution for third-line or later treatment of hypertension, and its efficacy in chronic kidney disease and ongoing exploration in obstructive sleep apnea suggest broader applicability in cardiorenal metabolic disorders. The market for hypertension treatments is large, and a novel mechanism of action like ASI could capture significant share, especially for resistant cases.

Comparison to Industry Standards

• The pivotal trials (Launch-HTN and Advance-HTN) demonstrated clinically meaningful and statistically significant reductions in systolic blood pressure, with Launch-HTN showing a placebo-adjusted reduction of -9.1 mmHg at week 6 and -11.6 mmHg at week 12, and Advance-HTN showing -7.9 mmHg at week 12. These reductions are competitive with or superior to some existing add-on therapies for resistant hypertension.
• The Explore-CKD trial's results, including a -7.5 mmHg placebo-adjusted systolic BP reduction and a -25.60% reduction in UACR, are significant. The UACR reduction is particularly notable as it indicates potential renal protective effects, a key outcome for CKD patients, and is comparable to the benefits seen with other renin-angiotensin-aldosterone pathway inhibitors like ACE inhibitors, ARBs, and SGLT2 inhibitors.
• The observed incidence of hyperkalemia (e.g., 2.1% to 3.2% confirmed in Advance-HTN, 5% in Explore-CKD) and modest eGFR decrease are anticipated side effects for drugs targeting the renin-angiotensin-aldosterone system, and appear to be within an acceptable range for this class of drugs, suggesting a favorable benefit-risk profile.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical trial results, increased cash runway, and progress towards NDA submission, which could lead to future revenue. Potential for dilution from future equity offerings.
• Employees: Continued employment and potential growth opportunities as the company advances towards commercialization.
• Patients (Hypertension, CKD, OSA): Potential for a new, effective treatment option for conditions with significant unmet needs.
• Mitsubishi Tanabe Pharmaceutical Company: Potential to receive significant commercial milestone payments and tiered royalties upon lorundrostat's approval and sales.

Next Steps

• Submit a New Drug Application (NDA) for lorundrostat in late 2025 or the first quarter of 2026.
• Report topline results from the Phase 2 Explore-OSA trial in the first quarter of 2026.
• Continue the ongoing Transform-HTN open-label extension trial to generate additional long-term efficacy and safety data for lorundrostat.
• Continue to fund clinical development, manufacturing, and pre-commercialization activities for lorundrostat.
• Evaluate the impact of new accounting standards (ASU 2024-03 and ASU 2023-09) on financial statements and disclosures.

Key Dates

Recommendation

The filing presents overwhelmingly positive clinical trial data for lorundrostat across multiple indications, including successful pivotal trials for hypertension and promising Phase 2 results for chronic kidney disease. This significantly de-risks the lead asset and provides a clear path to an NDA submission in the near term. The company has also substantially strengthened its balance sheet through recent capital raises, providing a robust cash runway for at least 12 months, which is critical for a clinical-stage biotech. While the company remains pre-revenue and incurs losses, the strong clinical efficacy, favorable safety profile, and solid financial position make it a compelling "strong buy" for investors looking for growth in the biopharmaceutical sector, especially given the large market opportunity in hypertension and cardiorenal diseases. The potential for lorundrostat in obstructive sleep apnea further adds to its long-term value proposition.

Keywords

Lorundrostat, Hypertension, Aldosterone Synthase Inhibitor, Cardiorenal, Chronic Kidney Disease, Obstructive Sleep Apnea, Clinical Trials, NDA Submission, Biopharmaceutical, Drug Development